Search Criteria: Practice "Healthcare" | 185 Results Found
January 15, 2019 Davis Polk Wins Six Practice Group of the Year Awards from Law360
January 9, 2019 Alan Denenberg Quoted in WSJ on Stalled IPO Market
January 9, 2019 Alan Denenberg Appears on CNBC to Discuss Impact of Government Shutdown on IPOs
January 3, 2019 Bristol-Myers Squibb Acquires Celgene
December 17, 2018 Hologic, Inc. $3 Billion Senior Secured Credit Facilities Refinancing
December 14, 2018 Secondary Offering of NeoGenomics, Inc. Common Stock
December 11, 2018 Davis Polk Advises Notre Dame Intermédica on Its R$2.7 Billion Equity Offering
December 10, 2018 Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
December 6, 2018 Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
November 30, 2018 DexCom, Inc. $850 Million Convertible Notes Offering
November 27, 2018 Taiwan Liposome Company, Ltd. Initial Public Offering
November 2, 2018 Orchard Therapeutics plc Initial Public Offering
October 31, 2018 Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
October 31, 2018 Innovent Biologics, Inc. HK$3.15 Billion (US$403.1 Million) Initial Public Offering
October 30, 2018 Gamida Cell Ltd. $50 Million Initial Public Offering
October 16, 2018 Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
October 11, 2018 Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
October 10, 2018 AtriCure, Inc. Common Stock Offering
October 9, 2018 Kodiak Sciences Inc. Initial Public Offering
October 5, 2018 Kala Pharmaceuticals, Inc. Common Stock Offering
September 27, 2018 Cipla Quality Chemical Industries Limited Initial Public Offering and USE Listing
September 24, 2018 Davis Polk Advises Shire on Its $2.325 Billion Concurrent Tender Offers
September 18, 2018 AbbVie Inc. $6 Billion Senior Notes Offering
September 18, 2018 Galapagos NV €296.2 Million Follow-On Offering of American Depositary Shares
September 17, 2018 Halfmoon Parent, Inc. $20 Billion Senior Notes Offering
September 17, 2018 Davis Polk Advises Roche Holdings on Its $1.4 Billion Notes Offering
September 10, 2018 Zai Lab Limited $150 Million Follow-On Offering of American Depositary Shares
August 30, 2018 Walgreens Boots Alliance $3.5 Billion Revolving Credit Facility
August 21, 2018 Illumina, Inc. $750 Million Convertible Senior Notes Offering
August 20, 2018 Zoetis Inc. $1.5 Billion Senior Notes Offering
August 17, 2018 Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
August 17, 2018 Davis Polk Advises AstraZeneca on Its $3 Billion SEC-Registered Notes Offering
August 14, 2018 REGENXBIO Inc. $175.5 Million Common Stock Offering
August 14, 2018 NeoGenomics Follow-On Offering
August 9, 2018 BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
August 2, 2018 Davis Polk Advises Pernix on Private Exchange Offers
August 1, 2018 Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
July 27, 2018 Teladoc, Inc. $348.9 Million Common Stock Offering
July 26, 2018 Constellation Pharmaceuticals Initial Public Offering
July 23, 2018 Allakos Inc. Initial Public Offering
July 18, 2018 Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants
July 17, 2018 CytomX Therapeutics, Inc. Follow-On Offering
July 16, 2018 Natera, Inc. $103.5 Million Follow-On Public Offering
July 2, 2018 Forty Seven, Inc. $112.6 Million Initial Public Offering
July 2, 2018 Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering
June 26, 2018 Magenta Therapeutics, Inc. Initial Public Offering
June 25, 2018 Aptinyx Inc. Initial Public Offering
June 19, 2018 Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
June 14, 2018 Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
June 11, 2018 Deciphera Pharmaceuticals Follow-On Offering
June 4, 2018 Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $2.05 Billion Refinancing
June 1, 2018 Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility
May 30, 2018 Iterum Therapeutics plc Initial Public Offering
May 29, 2018 Melinta Therapeutics, Inc. Common Stock Offering
May 25, 2018 Coherus BioSciences, Inc. $86.25 Million Follow-On Offering
May 25, 2018 Ardelyx, Inc. $50 Million Public Offering
May 22, 2018 AbbVie Inc. $3 Billion 364-Day Term Loan Credit Facility
May 22, 2018 Calyxt, Inc. Common Stock Offering
May 9, 2018 Davis Polk Advises Shire on Its Proposed Acquisition by Takeda
May 9, 2018 Davis Polk Advises We Doctor Holdings Limited on Its $500 Million Issuance of Shares
May 8, 2018 ASLAN Pharmaceuticals Initial Public Offering and NASDAQ Listing
May 7, 2018 Unity Biotechnology, Inc. $85 Million Initial Public Offering
May 4, 2018 Ping An Healthcare and Technology Company Limited HK$8.77 Billion ($1.12 Billion) Initial Public Offering
April 25, 2018 Davis Polk Advises McKesson on Its Acquisition of Medical Specialties Distributors
April 25, 2018 Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
April 23, 2018 Aeglea BioTherapeutics $36 Million Common Stock Offering
April 16, 2018 Davis Polk Advises Shire on the Sale of Its Oncology Business to Servier
April 10, 2018 Cellectis S.A. Follow-On Offering
April 4, 2018 PTC Therapeutics, Inc. Common Stock Offering
April 3, 2018 Davis Polk Advises iKang Healthcare on Its Acquisition by Yunfeng Capital and Alibaba
April 3, 2018 Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
March 27, 2018 Accelerate Diagnostics, Inc. $150 Million Convertible Senior Notes Offering
March 26, 2018 Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $1.5 Billion Refinancing
March 23, 2018 Xencor, Inc. Follow-On Offering
March 12, 2018 Corvus Pharmaceuticals, Inc. Common Stock Offering
March 8, 2018 Davis Polk Advises Agilent Technologies on Its Acquisition of Advanced Analytical Technologies
March 5, 2018 Atara Biotherapeutics, Inc. Follow-On Offerings
March 2, 2018 Anthem, Inc. $2.1 Billion Senior Notes Offering and Remarketing of Subordinated Notes
February 26, 2018 Aimmune Therapeutics Common Stock Offering
February 26, 2018 Davis Polk Advises ViewRay, Inc. on Its $59 Million Direct-Registered Equity Offering
February 20, 2018 Celgene $4.5 Billion Notes Offering
February 16, 2018 Avadel Pharmaceuticals $143.7 Million Exchangeable Senior Notes Offering
February 15, 2018 Davis Polk Advises Roche on Its Acquisition of Flatiron Health
February 15, 2018 Davis Polk Advises Affimed on Its $26.5 Million Offering of Shares
February 13, 2018 Davis Polk Advises Charles River on Its Acquisition of MPI Research
February 5, 2018 Seattle Genetics, Inc. $600 Million Equity Offering
February 1, 2018 Oliver Smith Profiled in The Deal
January 31, 2018 Varian Medical Systems Acquires Sirtex Medical
January 30, 2018 Solid Biosciences Inc. Initial Public Offering
January 29, 2018 Five Prime Therapeutics, Inc. Common Stock Offering
January 29, 2018 ConforMIS, Inc. Common Stock Offering
January 26, 2018 Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
January 26, 2018 Stemline Therapeutics, Inc. Common Stock Offering
January 23, 2018 Agios Pharmaceuticals, Inc. Common Stock Offering
January 19, 2018 Hologic, Inc. $1 Billion Senior Notes Offering
January 5, 2018 Davis Polk Advises TiGenix on Its Acquisition by Takeda
December 12, 2017 Denali Therapeutics Inc. Initial Public Offering
December 11, 2017 Revance Therapeutics, Inc. $190 Million Common Stock Offering
December 8, 2017 Editas Medicine, Inc. $50 Million Follow-On Offering
December 4, 2017 Davis Polk Advises Aetna on Its Acquisition by CVS Health
November 30, 2017 Anthem, Inc. Cash Tender Offers
November 21, 2017 Anthem, Inc. $5.5 Billion Senior Notes Offering
November 16, 2017 Davis Polk Advises Roche on Its €250 Million Cash Tender Offer
November 16, 2017 Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
November 10, 2017 Insulet Corporation Convertible Senior Notes Offering
November 10, 2017 Davis Polk Advises InflaRx N.V. on Its Initial Public Offering
November 9, 2017 Celgene $3 Billion Notes Offering
November 7, 2017 Davis Polk Advises McKesson Corporation on Its Acquisition of RxCrossroads from CVS Health Corporation
November 6, 2017 Allena Pharmaceuticals Initial Public Offering
November 6, 2017 Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
October 30, 2017 Davis Polk Advises Advanced Accelerator Applications on Its Acquisition by Novartis
October 30, 2017 Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
October 25, 2017 Davis Polk Advises ViewRay, Inc. on a $50 Million Direct Registered Equity Offering
October 20, 2017 Davis Polk Advises Auris Medical Holding AG on Its Registered Offering of Common Shares and Equity Line of Financing
October 16, 2017 Flexion Therapeutics, Inc. $122.4 Million Follow-On Offering
October 12, 2017 Davis Polk Advises China Biologic Products on Its Acquisition of Tianxinfu
October 10, 2017 Hologic, Inc. $350 Million Senior Notes Offering
September 29, 2017 Deciphera Pharmaceuticals Initial Public Offering
September 28, 2017 Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offerings of Common Stock and Warrants to Purchase Common Stock
September 26, 2017 Juno Therapeutics, Inc. $288 Million Follow-On Offering
September 22, 2017 Magellan Health, Inc. $400 Million Senior Notes Offering
September 22, 2017 Zai Lab Limited Initial Public Offering and NASDAQ Listing
September 19, 2017 Healthcare Trust of America, Inc. $500 Million At-the-Market Offering
September 15, 2017 Portola Pharmaceuticals Follow-On Offering
September 12, 2017 Zoetis Inc. $1.25 Billion Senior Notes Offering
August 23, 2017 Jazz Pharmaceuticals $500 Million Exchangeable Senior Notes Offering
August 18, 2017 Oxford Immunotec Global PLC Offering of Ordinary Shares
August 16, 2017 BeiGene, Ltd. Public Offering
August 10, 2017 Celgene $500 Million Notes Offering
August 10, 2017 Spark Therapeutics Follow-On Offering
August 7, 2017 Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
August 4, 2017 Davis Polk Advises Bristol-Myers Squibb Company on Its Acquisition of IFM Therapeutics
August 2, 2017 $3.1 Billion Financing for inVentiv’s Merger with INC Research
August 2, 2017 Davis Polk Advises AstraZeneca as Special Tax Counsel on Its Strategic Collaboration with Merck
August 2, 2017 Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
August 1, 2017 China Biologic Products Redomicile from Delaware to the Cayman Islands
August 1, 2017 Sienna Biopharmaceuticals Initial Public Offering
July 31, 2017 LabCorp Acquires Chiltern
July 28, 2017 Biotoscana Investments $377.7 Million Initial Public Offering
July 26, 2017 Davis Polk Advises Pernix Therapeutics Holdings, Inc. on Its Refinancing Transactions
July 25, 2017 Kala Pharmaceuticals, Inc. Initial Public Offering
July 24, 2017 Davis Polk Advises Mitsubishi Tanabe Pharma on Its Acquisition of NeuroDerm
July 19, 2017 Akcea Therapeutics Initial Public Offering
July 5, 2017 Mersana Therapeutics, Inc. Initial Public Offering
July 5, 2017 Dova Pharmaceuticals, Inc. Initial Public Offering
June 28, 2017 Royal Philips Acquires Spectranetics
June 28, 2017 Evolent Health, Inc. Common Stock Secondary Offering
June 27, 2017 Teladoc, Inc. $275 Million Convertible Senior Notes Offering
June 23, 2017 Bristol-Myers Squibb Company Debt Tender Offer
June 20, 2017 Loxo Oncology, Inc. Common Stock Offering
June 12, 2017 Davis Polk Advises AstraZeneca on Its $2 Billion SEC-Registered Notes Offering
June 12, 2017 Cardinal Health $5.2 Billion Notes Offering
June 7, 2017 NanoString Technology Public Stock Offering
May 31, 2017 Achaogen Common Stock Offering
May 30, 2017 Alnylam Pharmaceuticals, Inc. Common Stock Offering
May 19, 2017 Evolent Health, Inc. Common Stock Secondary Offering
May 12, 2017 DexCom, Inc. $350 Million Convertible Notes Offering
May 11, 2017 AMAG Pharmaceuticals, Inc. $300 Million Convertible Senior Notes Offering
May 9, 2017 Eli Lilly $2.25 Billion Notes Offering
May 2, 2017 Flexion Therapeutics $201.25 Million Convertible Senior Notes Offering
April 24, 2017 Agios Pharmaceuticals, Inc. Common Stock Offering
April 21, 2017 Galapagos NV €363.9 Million Follow-On Offering of American Depositary Shares
April 18, 2017 $4.5 Billion Bridge Facility for Cardinal Health, Inc.’s Acquisition of Stock and Assets from Medtronic plc
April 14, 2017 Abbott and Alere Amend Merger Agreement
March 31, 2017 Evolent Health Common Stock Secondary Offering
March 28, 2017 Medtronic $2 Billion Notes Offering
March 22, 2017 Davis Polk Advises Penumbra, Inc. on Its Follow-On Offering
March 22, 2017 Abbott Laboratories $2.9 Billion Exchange Offers and Consent Solicitations
March 22, 2017 Editas Medicine, Inc. $90 Million Follow-On Offering
March 21, 2017 Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $6.25 Billion Refinancing
February 27, 2017 Bristol-Myers Squibb Company $1.5 Billion Notes Offering
February 21, 2017 Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants to Purchase Common Shares
February 16, 2017 Hermes Pardini R$763 Million Initial Public Offering
February 13, 2017 Coherus BioSciences, Inc. Follow-On Offering
February 7, 2017 Davis Polk Advises McKesson Corporation on $1 Billion Notes Offering by Change Healthcare
February 1, 2017 Jounce Therapeutics, Inc. Initial Public Offering
January 25, 2017 Davis Polk Advises Affimed on Its $18 Million Offering of Shares
January 19, 2017 Davis Polk Successfully Represents Aetna in Patent Infringement Suit
March 31, 2016 Davis Polk Advised Affymetrix on Its Merger with Thermo Fisher
September 21, 2015 Davis Polk Wins Summary Judgment of Non-Infringement in Patent Litigation on Behalf of Transcend Medical, Inc.
September 2, 2015 Davis Polk Advises RoundTable Healthcare Partners on the Formation of Its Equity Fund IV and Capital Fund III
November 25, 2013 Davis Polk Advises Aetna on Its Acquisition of U.K.-Based InterGlobal Group
June 26, 2009 Second Circuit Affirms Dismissal of Securities Class Action Against AstraZeneca
February 2, 2009 Shareholder Plaintiff's Fee Petition in Roche-Ventana Merger Denied
July 25, 2008 AstraZeneca Wins Before California State Court of Appeals
News Search: